Wozyme DS 180mg/96mg/200mg Tablet is a combination pharmaceutical formulation containing Bromelain 180mg, Trypsin 96mg, and Rutoside 200mg, designed to provide anti-inflammatory, proteolytic, and vasoprotective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, facilitates the breakdown of proteins and exhibits anti-inflammatory and anti-edematous properties, making it effective in reducing swelling and pain associated with trauma, surgery, or inflammatory conditions. Trypsin, another proteolytic enzyme, enhances the degradation of necrotic tissue and fibrin, promoting wound healing and reducing inflammation. Rutoside, a bioflavonoid, strengthens capillary walls and improves microcirculation, thereby reducing capillary fragility and edema. The synergistic action of these components makes Wozyme DS suitable for managing conditions such as post-operative edema, soft tissue injuries, venous insufficiency, and inflammatory disorders. This tablet is typically administered orally under medical supervision, with dosage adjusted according to the clinical condition and patient response. Caution is advised in patients with hypersensitivity to any component, bleeding disorders, or concurrent anticoagulant therapy. Wozyme DS offers a multi-modal approach to inflammation and tissue repair, enhancing recovery and improving patient outcomes in various inflammatory and vascular conditions.